WO2007043061A1 - Combinaison antimalariale et méthodes de formulation - Google Patents

Combinaison antimalariale et méthodes de formulation Download PDF

Info

Publication number
WO2007043061A1
WO2007043061A1 PCT/IN2006/000005 IN2006000005W WO2007043061A1 WO 2007043061 A1 WO2007043061 A1 WO 2007043061A1 IN 2006000005 W IN2006000005 W IN 2006000005W WO 2007043061 A1 WO2007043061 A1 WO 2007043061A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
artesunate
pharmaceutical composition
amodiaquine
weight
Prior art date
Application number
PCT/IN2006/000005
Other languages
English (en)
Inventor
Premchand Godha
Yatish Kumar Bansal
Subhrangshu Sengupta
Nivedita Singh
Original Assignee
Ipca Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Ltd. filed Critical Ipca Laboratories Ltd.
Publication of WO2007043061A1 publication Critical patent/WO2007043061A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a novel combination of two compounds having antimalarial activity. Specifically, the present invention relates to the combination of two anti-malarial drugs, artesunate and amodiaquine. More specifically, the invention relates to the pharmaceutical composition of the two drugs and the process of preparation of the composition.
  • Artemisinin and its derivatives extracted from a herb used in traditional Chinese medicine, have shown important anti-malarial properties. . To date, resistance to artemisinin and its derivatives has not been reported, unlike other anti-malarial drugs. Artemisinin-based drugs including artesunate have been found to be effective against resistant strains of malaria when prescribed alone, but disease relapse commonly occurs. When artemisinin is combined with another effective anti-malarial drug, a shorter course of treatment is rapidly effective and recurrence of the disease is uncommon. Both artesunate and amodiaquine are widely used anti-malarial agents. One option for slowing the spread of resistance and improving treatment outcomes is the use of artemisinin combination therapy.
  • EP0362810 discloses an improved antimalarial composition and methods of treating malaria which employ a combination with on the one hand, one of the antimalarial agents, Artemisinine, Dihydroartemisinine, Arteether, Artemether, Artesunate and on the other hand, the antimalarial agent Quinidine alone or with Mefloquine and/or their pharmaceutically acceptable salts.
  • WO9202217 describes a synergistic antimalarial composition which comprises the antimalarial agent benflumetol and also an antimalarial agent from the artemisinine group such as artemether.
  • the composition can be formulated into solid dosage forms such as tablets and is useful for the treatment of drug resistant malaria.
  • US5219865 relates to oral or subcutaneous combinations of the malaria therapeutics artemisinine, dihydroartemisinine, arteether, artemether, artesunate or other artemisinine derivatives with one or more of the antimalarials chloroquine, 10-0- methylfloxacrine, quinine, mefloquine, amodiaquine, pyrimethamine, sulfadoxine and primaquine. But the examples do not describe artesunate or amodiaquin in a stable combination specifically.
  • compositions comprising of a therapeutically effective amount of a pharmaceutical agent(s), including artesunate and amodiaquine among others.
  • a pharmaceutical agent(s) including artesunate and amodiaquine among others.
  • the compositions make use of active agents, polymers and solvents.
  • US Patent 5,656,286 describes transdermal drug delivery system, comprising of a single drug or their combinations wherein among anti-malarial drugs artesunate and amodiaquine are mentioned.
  • WO03075927 discloses pharmaceutical combinations of artesunate and mefloquine which have antimalarial activity. This invention is concerned with the effective amounts of said combinations and their use in the treatment of malaria in a 3 -day course.
  • the combination of the present invention is administered preferably orally, most preferably as tablets.
  • the objective of the invention is to formulate a stable pharmaceutical composition comprising the combination of artesunate and amodiaquine as a single dosage form. More particularly the objective of the invention to present a combination of the two drugs, artesunate and amodiaquine in the form of a stable solid dosage form.
  • Another objective of the invention is to overcome the chemical incompatibility of the two drugs by formulating a tablet-in-tablet dosage form.
  • the formulation can also be presented as other solid dosage forms such as capsule, pills, granules, sachets and such like, in a mutually protected environment such as coated granules.
  • Yet another objective of the invention is to present a process for the manufacturing of the combination of artesunate and amodiaquine in a single dosage form, which contributes to enhanced therapeutic benefits and patient convenience.
  • a novel combination for the preparation of an anti-malarial compound comprising of artesunate and amodiaquine and the process thereof is disclosed.
  • This combined preparation relates to artesunate 25mg with amodiaquine 75mg, artesunate 50mg with amodiaquine 150 mg, artesunate lOOmg with amodiaquine 300mg and artesunate 200mg with amodiaquine 600mg and pharmaceutically accepateble excipients.
  • the combination composition of artesunate and amodiaquine is preferably used as a solid formulation, for example, in the form of tablets. It can be used in the form of tablet-in-tablet, pills, granules, capsule or sachets.
  • the present invention relates to a novel combination of pharmaceutically active antimalarial compounds artesunate and amodiaquine, and to the use of the combined preparation in anti-malarial therapy. Accordingly, this invention is concerned with the pharmaceutical composition of this combination and the process involved in the manufacturing of this product.
  • the dose range of artesunate in the present invention is 25 mg to 200 mg and that of amodiaquine is 75 mg to 600 mg.
  • a preferred combination product according to the present invention would comprise of artesunate and amodiaquine in admixture with commonly known but carefully screened pharmaceutical excipients belonging to the categories of diluents, binders, flavours, preservatives, pH adjusters, alkalising agents, disintegrating agents, film formers, plasticizers, lubricants and/or glidants.
  • the above typical pharmaceutical excipients are incorporated into the formulation singularly or in combinations to prepare a combination product that is physically and chemically stable over the studied period.
  • the composition may be provided as a shaped composition such as a tablet, in which case the composition typically includes one or more conventional excipients for tablet formulation such as diluents, selected from the group of microcrystalline cellulose, lactose, maize starch, mannitol, pregelatinised starch, dibasic calcium phosphate and the like; disintegrants selected from maize starch, modified starch, croscarmellose sodium and such; binders selected from cellulose derivatives, maize starch and polyvinyl pyrrolidone.
  • diluents selected from the group of microcrystalline cellulose, lactose, maize starch, mannitol, pregelatinised starch, dibasic calcium phosphate and the like
  • disintegrants selected from maize starch, modified starch, croscarmellose sodium and such
  • Lubricants are selected preferably from the group containing magnesium stearate, talc and colloidal silicon dioxide; coating ingredients include pharmaceutically acceptable polymers, plasticizers like polyethylene glycol, opacifier like titanium dioxide, glidant like talc, colours, and other miscellaneous auxiliaries required for the processing and stability of the product.
  • the present invention provides a wet granulation method for formulation of tablet, wherein artesunate, in the particle range of 50 ⁇ or less is separately granulated with an admixture of pharmaceutically acceptable excipients and compressed into tablets. Then, this artesunate tablet may be film-coated after which it can be compressed so as to form the core of amodiaquine tablets by tablet-in-tablet technology.
  • the preferred diluent in the artesunate tablet is mannitol and lactose in the range of 2 - 15% on a dry weight basis.
  • the preferred disintegrant is cross carmellose sodium, used intra-granularly and extra granular Iy in the range of 0.5 - 7% based on the weight of the formulation.
  • the resultant dry mix is granulated with an alcoholic solution containing hydroxypropyl cellulose, as binder in the range of 0.1 - 0.5%, and the solvent is evaporated from the granulate by drying in a fluid bed dryer at approximately 6O 0 C to achieve a specified moisture content, determined by loss on drying.
  • the dried granulation is reduced with a screening mill.
  • the granules are lubricated by blending with remaining part of sodium starch glycollate, colloidal silicon dioxide as glidant, in the range of 0.05-0.6% on a dry weight basis, based on the weight of the formulation, and magnesium stearate as lubricant in the range of 0.1-0.4% on a dry weight basis, based on the weight of the formulation,.
  • This blend was compressed into tablets, to a desired target on a suitable tablet press.
  • the resultant tablets were suitably film-coated in a coating pan with an appropriate non- aqueous/alcoholic hydroxypropyl methylcellulose (HPMC) based film coat.
  • HPMC non- aqueous/alcoholic hydroxypropyl methylcellulose
  • the coating solution consisted of hydroxypropylmethylcellulose as the film former in the range of 2-6%, polyethylene glycol 6000 as plasticizer in the range of 0.1-0.4%, titanium oxide in the range of 0.2-0.8%. as opacifier and talc as glidant in the range of 0.6-1.7%.
  • the coating suspension is formulated in organic solvent system consisting of isopropyl alcohol and methylene chloride.
  • Amodiaquine is granulated separately by blending with pregelatinized starch as diluent in the range of 5-10% on a dry weight basis, based on the weight of the formulation. This is followed by granulating with starch paste, in the range of 5-20% on a dry weight basis, based on the weight of the formulation.
  • the wet granulate were suitably dried in a fluid bed dryer at approximately 60 0 C and sized with a screening mill. Lubrication was achieved by blending with magnesium stearate.
  • the combination product is prepared by incorporating the coated tablet of artesunate into the core of amodiaquine granules to form a tablet-in-tablet using a suitable tablet press.
  • the manufacturing process comprises of the steps of: a) preparation of inner tablet of artesunate where artesunate was separately granulated with an admixture of pharmaceutically acceptable excipients and compressed into tablets; b) artesunate tablet thus prepared were film-coated for protection; c) amodiaquine was separately granulated to form outer tablet; d) atesunate coated tablets was compressed within amodiaquine granules so as to form the core of amodiaquine tablets by tablet-in-tablet technology.
  • Film-coated artesunate tablet comprised of the inner tablet of the tablet-in-tablet combination.
  • the formulation for preparation of 100 mg strength artesunate tablets had the following composition: Table 1
  • the active ingredient and the diluents were blended together and passed through relevant sieves.
  • the resultant blend was further granulated in a high shear mixer with the binder solution prepared by dispersing hydroxypropyl cellulose in isopropyl alcohol. After the wet mass was sized through suitable sieves, the solvent was evaporated from granulate by drying at 50-55°C to achieve the desired moisture content of the granules, determined by loss on drying.
  • the dried granules were reduced by sizing through suitable sieves and lubricated, cross caramellose sodium, colloidal silicon dioxide and magnesium stearate were incorporated as lubricants to produce the final compression blend.
  • the resultant lubricated granules were compressed into tablets, to a desired target on a suitable tablet press.
  • Artesunate tablets prepared were film-coated in a coating pan with an appropriate non-aqueous/alcoholic hydroxypropylmthylcellulose (HPMC) based film coat.
  • the film coat was designed to act as a protective barrier for the core artesunate tablets to shield artesunate from direct exposure to the outer amodiaquine as the two active ingredients are incompatible.
  • the typical level of film coat applied to the tablets was about 5% w/w.
  • Film coating of artesunate tablet cores made in Example I was performed with the following coating solution:
  • Tablets of example 1 were coated with 5% of this solution per tablet weight using a film coating device to obtain the artesunate tablets to be compressed within amodiaquine granules to form the tablet-in-tablet product of the present invention.
  • Outer Tablets of example 1 were coated with 5% of this solution per tablet weight using a film coating device to obtain the artesunate tablets to be compressed within amodiaquine granules to form the tablet-in-tablet product of the present invention.
  • the formulation for preparation of amodiaquine granules had the following composition:
  • Amodiaquine granules were prepared by blending active ingredient with pregelatinised starch, sizing through appropriate sieves and granulation with maize starch paste in purified water in high shear mixer. The wet mass was sized and dried at 60°C to achieve the desired moisture content of the granules, determined by loss on drying. The dried granules were reduced by sizing through suitable sieves and suitably lubricated.
  • Each tablet-in-tablet comprised of 100 mg of artesunate and 300 mg of amodiaquine of total weight 740 mg and containing 220 mg of inner artesunate coated tablet and 520 mg of outer amodiaquine tablet.
  • the inner artesunate tablets are compressed in a regular tablet press, then film coated.
  • the tablet-in-tablet were produced on a specialized tablet press which operated by a specialized pressing procedure, whereby inner tablets are fed into the tablet-in-tablet press with amodiaquine granules and the press operated again such that a final product is of artesunate tablet inside amodiaquine.
  • Tablets comprising of 50 mg artesunate with 150 mg amodiaquine, 25 mg artesunate with 75 mg amodiaquine and 200 mg artesunate with 600 mg amodiaquine were similarly prepared.
  • the artesunate coated tablets and amodiaquine granules can be optionally filled into suitable capsule shells using techniques of partial filling method and tablet-in-capsule method.
  • This invention intends to provide a pharmaceutically acceptable combination for oral use that is a stable preparation of the combination of artesunate and amodiaquine.
  • the present invention relates to the process for preparation of a stable solid oral pharmaceutical combination of the two sensitive active compounds which are chemically incompatible with each other, therefore prepared as a specialized tablet-in- tablet technology, to protect the two active compounds from each other. Further aspects of this invention suggest that the pharmaceutical combination of the present invention obtained by the process as claimed possesses an enhanced antimalarial action in drug-resistant cases where artesunate and amodiaquine in combination can effectively delay or prevent the resistance, and therefore, the amount of drugs used can be reduced as compared with monotherapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur une préparation pharmaceutique orale, solide et stable comprenant une combinaison de deux composés antimalariaux incompatibles, l'artésunate et l’amodiaquine, avec des excipients de qualité pharmaceutique, sous la forme d'un comprimé multicouches, ainsi que le procédé d'élaboration de ladite préparation.
PCT/IN2006/000005 2005-10-11 2006-01-04 Combinaison antimalariale et méthodes de formulation WO2007043061A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1279/MUM/2005 2005-10-11
IN1279MU2005 2005-10-11

Publications (1)

Publication Number Publication Date
WO2007043061A1 true WO2007043061A1 (fr) 2007-04-19

Family

ID=36603070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000005 WO2007043061A1 (fr) 2005-10-11 2006-01-04 Combinaison antimalariale et méthodes de formulation

Country Status (1)

Country Link
WO (1) WO2007043061A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008146178A2 (fr) 2007-05-30 2008-12-04 Wockhardt Research Centre Nouvelle forme posologique de comprimé
WO2011032318A1 (fr) * 2009-09-21 2011-03-24 上海复星普适医药科技有限公司 Comprimé à base d'un complexe d'artésunate et de chlorhydrate d'amodiaquine et son procédé de préparation
CN101632649B (zh) * 2008-07-23 2013-05-08 Ss制药株式会社 薄膜包衣用组合物
US11090291B2 (en) * 2013-03-14 2021-08-17 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
WO2022039523A1 (fr) * 2020-08-19 2022-02-24 주식회사 노브메타파마 Utilisation d'une composition comprenant de l'amodiaquine et un médicament à base d'artésunate comme principe actif pour la prévention, l'atténuation ou le traitement du diabète sucré de type 2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet
EP0290959A2 (fr) * 1987-05-08 1988-11-17 Hoechst Aktiengesellschaft Mélange de médicaments pour la prophylaxie et thérapie de la malaria
WO2005023304A2 (fr) * 2003-09-04 2005-03-17 Cipla Limited Compositions antipaludeennes et procede associe
CN1698618A (zh) * 2005-06-07 2005-11-23 桂林制药有限责任公司 青蒿琥酯与盐酸阿莫地喹双层片及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet
EP0290959A2 (fr) * 1987-05-08 1988-11-17 Hoechst Aktiengesellschaft Mélange de médicaments pour la prophylaxie et thérapie de la malaria
WO2005023304A2 (fr) * 2003-09-04 2005-03-17 Cipla Limited Compositions antipaludeennes et procede associe
CN1698618A (zh) * 2005-06-07 2005-11-23 桂林制药有限责任公司 青蒿琥酯与盐酸阿莫地喹双层片及其制备方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008146178A2 (fr) 2007-05-30 2008-12-04 Wockhardt Research Centre Nouvelle forme posologique de comprimé
CN101632649B (zh) * 2008-07-23 2013-05-08 Ss制药株式会社 薄膜包衣用组合物
WO2011032318A1 (fr) * 2009-09-21 2011-03-24 上海复星普适医药科技有限公司 Comprimé à base d'un complexe d'artésunate et de chlorhydrate d'amodiaquine et son procédé de préparation
US11090291B2 (en) * 2013-03-14 2021-08-17 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US11160792B2 (en) 2013-03-14 2021-11-02 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US11229627B1 (en) 2013-03-14 2022-01-25 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US11311516B2 (en) 2013-03-14 2022-04-26 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US11484527B2 (en) 2013-03-14 2022-11-01 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
WO2022039523A1 (fr) * 2020-08-19 2022-02-24 주식회사 노브메타파마 Utilisation d'une composition comprenant de l'amodiaquine et un médicament à base d'artésunate comme principe actif pour la prévention, l'atténuation ou le traitement du diabète sucré de type 2

Similar Documents

Publication Publication Date Title
AU726212B2 (en) Fast-dissolving galanthamine hydrobromide tablet
EP1501485B1 (fr) Comprime a forte charge en substance medicamenteuse
US20230293695A1 (en) Tamper Resistant Pharmaceutical Formulations
EP1524981B1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
CA2911212A1 (fr) Compositions de cenicriviroc et leurs procedes de fabrication et d'utilisation
EP2854773B1 (fr) Composition pharmaceutique d'entecavir, et procédé de fabrication
WO2010128525A2 (fr) Préparation d'ivabradine dans le traitement des maladies cardiovasculaires
NZ281236A (en) Tablet (composition) comprising paracetamol (aceta-minophen) and domperidone (5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol -1-yl) propyl]-4-piperidinyl]-1,3-dihydra-2H-benzimidazol-2-one)
US20070104789A1 (en) Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
WO2007043061A1 (fr) Combinaison antimalariale et méthodes de formulation
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2005023304A2 (fr) Compositions antipaludeennes et procede associe
US20230301941A1 (en) Abuse-deterrent dosage forms containing esketamine
US20050287177A1 (en) Pharmaceutical compositions
US20150141376A1 (en) Pharmaceutical compositions of anti-viral compounds and process for preparation thereof
US20080145422A1 (en) Galantamine tablet formulation
CN105407876A (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈可分散的片剂形式的抗结核病的稳定的药物组合物及其制备方法
AU2014295098B2 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
US20090324715A1 (en) High dose oral pharmaceutical compositions of artemether and lumefantrine
EP1490034B1 (fr) Nouvelles compositions pharmaceutiques pour une combinaison antihistaminique-decongestive et procede de fabrication de ces compositions
WO2007036947A1 (fr) Composition anti-paludéenne à libération retardée
WO2021257461A1 (fr) Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne
AU2020404130A1 (en) A pharmaceutical oral dosage form of Q203
US20040192706A1 (en) Method and compositions for treating anxiety
WO2008008057A1 (fr) Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06745193

Country of ref document: EP

Kind code of ref document: A1